Strategy for preventing peritoneal dialysis failure

Contributions to Nephrology

Volumn 131, Issue , 2001, Pages 114-124

  Cancarini, Giovanni ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; DIALYSIS FLUID; GLUCAN; GLUCOSE; GLYCEROL; HYPERTONIC SOLUTION; ICODEXTRIN;

CHEMISTRY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG EFFECT; DRUG PACKAGING; EQUIPMENT; EQUIPMENT DESIGN; HUMAN; METABOLISM; METHODOLOGY; OSMOTIC PRESSURE; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PERMEABILITY; PRESSURE; REVIEW; TREATMENT FAILURE;

AMINO ACIDS; DIALYSIS SOLUTIONS; DRUG PACKAGING; EQUIPMENT CONTAMINATION; EQUIPMENT DESIGN; GLUCANS; GLUCOSE; GLYCEROL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTONIC SOLUTIONS; OSMOTIC PRESSURE; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PERITONITIS; PERMEABILITY; PRESSURE; TREATMENT FAILURE;

EID: 0035526688     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (43)

1. Rottembourg J, Issad B, Gallego JL, Degoulet P, Aime F, Gueffaf B, Legrain M: Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1983;19:397-403.
2. Cancarini GC, Brunori G, Camerini C, Brasa S, Manili L, Maiorca R: Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit Dial Bull 1986;6:77-79.
3. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, Nolph KD, Pollock CA, Prowant B, Farrell PC: The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991;37:598-604.
4. Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P: Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1995;15(suppl 7):61-70.
5. Di Paolo NJ, Garosi G: Peritoneal sclerosis. J Nephrol 1999;12:347-361.
6. Struijk DG, Krediet RT, Koomen GC, Boeschoten EW, Hoek FJ, Arisz L: A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994;45:1739-1744.
7. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994;23:64-73.
8. Di Paolo N, Buoncristiani U, Capotondo L, Gaggiotti E, De Mia M, Rossi P, Sansoni E, Bernini M: Phosphatidylcholine and peritoneal transport during peritoneal dialysis. Nephron 1986;44:365-370.
9. Breborowicz A, Wieczorowska K, Witowski J, Martis L, Oreopoulos DG: Phosphatidylcholine and chondroitin sulphate in peritoneal dialysis fluids to preserve membrane function. Perit Dial Int 1994;14(suppl 3):139-144.
10. Martinsson E, Nilsson-Thorel CB, Wieslander A, Kjellstrand P, Boberg U: Toxicity of heat-sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO Trans 1992;38:370-372.
11. Kjellstrand P, Martinsson E, Wieslander AP, Holmqvist B: Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature. Perit Dial Int 1995;15:26-32.
12. Coles GA: Biocompatibility and new fluids. Perit Dial Int 1999;19(suppl 2):267-270.
13. Ho-dac-Pannekeet MM, Weiss MF, de Waart DR, Erhard P, Hiralall JK, Krediet RT: Analysis of non-enzymatic glycosylation in vivo: Impact of different dialysis solutions. Perit Dial Int 1999; 9(suppl 2)68-74.
14. Cendoroglo M, Sundaram S, Jaber BL, Pereira BJG: Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. Am J Kidney Dis 1998;31:273-282.
15. Dobbie JW: Ultrastructure and pathology of the peritoneum in peritoneal dialysis; in Gokal R, Nolph KD (eds): The Textbook of Peritoneal Dialysis. Dordrecht, Kluwer, 1994, pp 17-44.
16. Gambaro G, Fracasso A, Re G, Fries W, Baggio B, Bazzato G: Glycosaminoglycans improve peritoneal transport and fibrosis in rats with peritoneal sclerosis induced by diethylphthalate. J Am Soc Nephrol 1994;5:448.
17. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG: Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994;67:346-350.
18. Bazzato G, Fracasso A, Gambaro G, Baggio B: Use of glycosaminoglycans to increase the efficiency of long-term continuous peritoneal dialysis. Lancet 1995;346:740-741.
19. Serlie MJM, Struijk DG, de Block K, Krediet RT: Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD. Adv Perit Dial 1997;13:29-32.
20. Wieslander AP, Deppish R, Svensson E, Forsback G, Speidel R, Rippe B: In vitro biocompatibility of a heat-sterilized, low-toxic and less acid fluid for peritoneal dialysis. Perit Dial Int 1995;15:158-164.
21. Dawnay AB, Millar DJ: Glycation and advanced glycation end product formation with icodextrin and dextrose. Perit Dial Int 1997;17:52-58.
22. Cappelli G, Bandiani G, Cancarini GC, Feriani M, Dell'Aquila R, Saffiotti S, Spisni C, Stingone A, Orazi E, Ballocchi S, Renaux JL: Low concentration of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag. Adv Perit Dial 1999;15:238-242.
23. Mahiout A, Brunkhorst R: Pyruvate anions neutralize peritoneal dialysate cytotoxicity. Nephrol Dial Transplant 1995;10:391-394.
24. Feriani M, Biasioli S, Borin D, Bragantini L, Brendolan A, Chiaramonte S, Dell'Aquila R, Fabris A, Ronco C, La Greca G: Bicarbonate buffer for CAPD solution. Trans Am Soc Artif Intern Organs 1985;31:668-672.
25. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J: Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993;13:296-301.
26. Cancarini GC, Faict D, De Vos C, Guiberteau R, Tranaeus A, Minetti L, Maiorca R: Clinical evaluation of a peritoneal dialysis solution with 33 mmol/l bicarbonate. Perit Dial Int 1998;18:576-582.
27. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue DT, Cancarini GC, Maiorca R, Tranaeus A, Faict D, de Vos C: A randomized controlled trial of a bicarbonate- and bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997;17:48-51.
28. Coles GA, O'Donoghue DJ, Pritchard N, Ogg CS, Jani FM, Gokal R, Cancarini GC, Maiorca R, Tranaeus A, De Vos C, Hopwood A, Faict D: A controlled trial of two bicarbonate-containing dialysis fluids for CAPD - Final report. Nephrol Dial Transplant 1998;13:3165-3171.
29. Manahan FJ, Ing BL, Chan JC, Gupta DK, Zhou FQ, Pal I, Rahman M: Effects of bicarbonate-containing versus lactate-containing peritoneal dialysis solutions on superoxide production by human neutrophils. Artif Organs 1989;13:495-497.
30. Scham bye HT, Pedersen BF, Chrinstenses HK, Berthelsen H, Wang P: The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate lactate ratios. Perit Dial Int 1993;13(suppl 2):116-118.
31. Yatzidis H: A new stable bicarbonate dialysis solution for peritoneal dialysis: Preliminary report. Perit Dial Int 1993;11:224-227.
32. Yatzidis H: A new single bicarbonate CAPD solution; in LaGreca G, Ronco C, Feriani M (eds): Peritoneal Dialysis. Milano, Wichtig, 1991, pp 151-157.
33. Yatzidis H: Enhanced ultrafiltration in rabbits with bicarbonate glycylglycine peritoneal dialysis solution. Perit Dial Int 1993;13:302-306.
34. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F: CAPD with an amino acid dialysis solution: A long-term cross-over study. Kidney Int 1989;35:1189-1194.
35. Kopple JD, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink LD, Martis L, Algrim C, Serkes KD, Vonesh E, Jones MR: Treatment of malnourished CAPD ptients with an amino acid-based dialysate. Kidney Int 1995;47:1148-1157.
36. Garosi G, Gaggiotti E, Monaci G, Brardi S, Di Paolo N: Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit. Perit Dial Int 1998;18:610-619.
37. Burke RA, Moberly JB, Patel H, Shockley TR, Martis L: Maltose and isomaltose in uremic plasma following icodextrin administration. Adv Perit Dial 1998;14:120-123.
38. Gokal R, Mistry CD, Peers E, and the MIDAS Study Group: A United Kingdom multicenter study of icodextrin in continuous peritoneal dialysis. Perit Dial Int 1994;14(suppl 2):22-27.
39. Stein A, Peers E, Hattersley J, Harris K, Feehally J, Walls J, and MIDAS Study Group: Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994;14(suppl 2):51-54.
40. 2-microglobulin in continuous ambulatory peritoneal dialysis: Influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 1990;5:513-519.
41. Liberek T, Topley N, Mistry CD, Coles GA, Morgan T, Quirk RA, Williams JD: Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993;13:104-111.
42. de Fijter CWH, Verbrugh HA, Oe LP, Heezius E, Donker AJM, Verhoef J, Gokal R: Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993;21:411-418.
43. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, Donker AJ: Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-hour dialysate creatinine clearance. Nephrol Dial Transplant 1997;12:550-553.